West Pharmaceutical Services Inc. (WST) Sets New 52-Week High at $82.64
Shares of West Pharmaceutical Services Inc. (NYSE:WST) reached a new 52-week high during trading on Monday . The stock traded as high as $82.64 and last traded at $82.57, with a volume of 131,994 shares changing hands. The stock had previously closed at $81.56.
WST has been the subject of several analyst reports. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $91.00 price objective for the company in a research note on Friday, August 5th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $90.00 price objective (up from $69.00) on shares of West Pharmaceutical Services in a research note on Friday, May 13th. Finally, Jefferies Group reaffirmed a “hold” rating and set a $67.00 price objective on shares of West Pharmaceutical Services in a research note on Thursday, June 9th.
The company’s 50 day moving average is $80.10 and its 200-day moving average is $72.72. The company has a market capitalization of $6.04 billion and a PE ratio of 60.05.
West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 28th. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.03. During the same quarter in the prior year, the business earned $0.47 earnings per share. The business had revenue of $388 million for the quarter, compared to analyst estimates of $384.58 million. The firm’s revenue was up 7.9% on a year-over-year basis. On average, analysts predict that West Pharmaceutical Services Inc. will post $2.23 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 3rd. Stockholders of record on Wednesday, July 20th were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Monday, July 18th. This represents a $0.48 annualized dividend and a dividend yield of 0.58%.
In other news, Director Paula A. Johnson sold 3,042 shares of the firm’s stock in a transaction dated Tuesday, August 23rd. The stock was sold at an average price of $81.55, for a total transaction of $248,075.10. Following the completion of the sale, the director now directly owns 38,450 shares in the company, valued at $3,135,597.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel Malone sold 3,950 shares of the firm’s stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $74.95, for a total value of $296,052.50. Following the sale, the vice president now owns 30,666 shares of the company’s stock, valued at $2,298,416.70. The disclosure for this sale can be found here.
An institutional investor recently raised its position in West Pharmaceutical Services stock. Schwab Charles Investment Management Inc. raised its stake in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 6.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 302,423 shares of the company’s stock after buying an additional 19,121 shares during the period. Schwab Charles Investment Management Inc. owned 0.42% of West Pharmaceutical Services worth $18,212,000 as of its most recent SEC filing.
West Pharmaceutical Services, Inc is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s products include stoppers and seals for vials, prefillable syringe components and systems, components for intravenous and blood collection systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.